New Schizophrenia Medications In Development (2015)

[Opus]

20+ New Schizophrenia Medications In Development (2015) - Mental Health Daily

[insidemind]

Thanks for sharing.

[everhopeful]

AQW051

MIN-101

Both look interesting.

OMS-824 sounds like Sci fi

Which of the new pipeline drugs for schizophrenia are most appealing?

Many drugs under development are marketed as “novel” new treatments, when in reality they’re nothing more than uncreative revisions of past-drugs. There’s definitely a place and a market for minor tweaks to older formulas. Patients are hoping that these tweaks provide similar efficacy to proven antipsychotics with less side effects and/or an improved modalities of administration.

Several developments are clearly piggybacking off of time-tested antipsychotics and will likely have success. These include the drugs: RBP-7000 (an improved injectable version of Risperdal), Aripiprazole Lauroxil (an improved injectable version of Abilify), and ALKS 3831 (a drug that combines Zyprexa and Samidorphan). Nearly all of these formulations should serve as slight improvements over previous medications.

Drugs in development that may be equally as effective as current-market atypical antipsychotics for management of positive and negative symptoms include: Cariprazine (targeting the D2 and D3 receptors), ITI-007 (targeting 5-HT2A receptors significantly more than D2), and MIN-101 (targeting 5-HT2A and Sigma-2 receptors). The drug ADX-1149 may be the first of a new class of antipsychotics that modulate glutamatergic activity.

In addition to the development of new antipsychotics, most pharmaceutical companies are investing money for the development of drugs that reverse cognitive impairment associated with schizophrenia. The drugs in development for the treatment of cognitive impairment vary in their targets. A majority of these “cognitive enhancers” are targeting the alpha-7 nicotinic acetylcholine receptors as agonists.

A few are focused on inhibiting PDE (phosphodiesterase) at various PDE receptors including: PDE10, PDE10A (specifically), or PDE1. Other unique targets for enhancing cognitive function among those with schizophrenia-induced deficits include: 5-HT6 receptors, AMPA receptors, glyT1 receptors, and H3 histamine receptors. Another agent that may improve depression as an adjunct is NW-3509, which functions as a VGSC (voltage-gated sodium channel) modulator.

Which new schizophrenia drugs are you most excited about?
If you have schizophrenia, study schizophrenia, and/or know someone with schizophrenia – is there any particular drug that you’re most excited about compared to the rest? Mention which drug you’re most excited about in the comments section below. Discuss whether you believe certain substances will be safer and more effective than currently available treatments.

When considering the significant number of cognitive enhancers being developed for schizophrenia, which target do you think will provide the greatest benefit with the fewest side effects? The pharmaceutical companies seem to have gone “all in” on targeting the alpha-7 nACh receptor and are ramping up production of PDE inhibitors. It is hoped that some of these developments will significantly improve the quality of life for those with schizophrenia.

[hippogal]

OMS 824

I’ve always wanted to be super intelligent…

example, PDE4B inhibition in mice results in super-intelligence and significantly less anxiety.

Hippo

[insidemind]

Yes, I want to be a genius to take these drugs under the guise of sz.

[YoungSchizo]

Thanks for sharing man, bookmarked it! I’ve been looking for this list for quite some time.

Usually I’m very good at finding data on (upcoming) drugs but Zicronapine got me confused. There is so little information available I can’t have a clear view if it will be submitted/launched anytime soon. Only thing I can find is that it’s in phase III and is expected to submitted in 2015/16 in Europe but all additional data, barely can find anything (fucking frustrating). Anyone can chime in?

[Green]

ItI-007 I’m looking forward to

[Opus]

Lu AF35700 is a drug under development by Lundbeck and is currently in Phase I clinical trials. It is believed to be an improvement over Zicronapine (Lu 31-130), an atypical antipsychotic that had already advanced through Phase II clinical trials, but was abandoned by Lundbeck.

[austinsdad]

Thanks man that’s a good read

[YoungSchizo]

It’s still says it’s in phase III trials in Europe, results expected this year. I don’t know if they gonna publish the trial results but what I do know for almost sure Lundback maybe took this decision for a tactical reason. Zicronapine has shown statically significant positive results in phase II trials but, even though phase III trials are ongoing and are not terminated, I guess it’s never gonna end up on the market because they’re going to improve this drug. Don’t like the decision though, the more options the better.

[Opus]

I think it has been scrapped its not on Lundbecks website so I dont think its coming out, unless some other company brought the rights to it. Or unless they changed the name to Rexulti.

[YoungSchizo]

http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5028

[Opus]

That is an out of date website like I said its not on lundbecks website whereas this site you just gave me says the company is lundbeck it has been canceled man im sorry but it seems like that is what has happend to that drug.

[YoungSchizo]

This site is the official site for medicine information of the UK. It’s never out of date, it actually is always up to date with every change. That Zicronapine has been cancelled to be improved that I already know.

[insidemind]

One medication I saw on the list worked on AMPA receptors. So do racetams.

[BlueFlame]

Amazing list, would really love to see more post like this!